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E

quitable access to essential medicines and diagnostic tools is crucial for improving global public health
and promoting sustainable health development efforts. Many individuals suffering from health challenges around the world still do not have access to existing life-saving interventions due to lack of availability and high costs. The devastating effects of these inequities and discussions about their solutions have
been at the forefront during the COVID-19 pandemic.
Health experts have long been working to identify effective methods of increasing access to medicines (AtM) that also incentivize
research and development (R&D) by drug manufacturers. In the
last two decades, the number of industry-led AtM programs implemented has substantially increased [1], with the pharmaceutical industry more openly recognizing a human rights obligation to improve access to medicines [2]. As argued by the Lancet
Commission on Essential Medicines Policies, despite the existence of
many industry-led AtM programs and the independent AtM Index that ranks 20 of the world's largest R&D-based pharmaceutical companies, rigorous evaluation remains a key challenge [3].
In response, the 2021 AtM Index report adapted various indicators to expand how it measures companies'
evaluation efforts and used tighter analytical framework centered on governance of access, research and development, and product delivery [4]. Figure 1 illustrates a representative set of indicators that were changed
between the 2018 and 2021 reports, with a full listing provided in Figure S1 in the Online Supplementary
Document. This most recent report was released in January 2021 to assess the actions taken by pharmaceutical companies to expand access to medicine for people living in low- and middle-income countries. It
also captures the industry’s response to the ongoing pandemic, identifying 63 new R&D projects in companies’ pipelines targeting COVID-19. The report also highlighted that the COVID-19 pandemic has caused

We offer a timely summary of the latest efforts to improve the evaluation of industry-led
access to medicines (AtM) programs, highlighting the recently released 2021 Access
to Medicines Index Report and the Second
World Health Organization (WHO) Model List
of Essential In Vitro Diagnostics.
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further problems with funding competition for other AtM initiatives, such as to
combat malaria, TB, and HIV/AIDS [5].
The Index reported that all 20 companies assessed now take steps to measure
outcomes of AtM initiatives, up from 13
companies in 2018. Outcomes are made
public for more than half of initiatives assessed (43 of 82). Also released in January
2021 was the Second World Health Organization (WHO) Model List of Essential
In Vitro Diagnostics (EDL), which provides a comprehensive list of diagnostic
tests necessary for universal health coverage that can be tailored to local circumstances [6]. The latest edition was revised
to include COVID-19 nucleic acid amplification and antigen detecting tests as a
necessary In Vitro Diagnostics. The WHO
has previously worked with many countries to make noncommunicable disease
Figure 1. A small representative set of indicators are presented that were changed between
diagnostic testing available in low- and
the 2018 and 2021 Access to Medicines Index reports. A comprehensive listing of indimiddle-income countries, which has led
cators and the changes between those used in 2018 and 2021 are provided in Figure S1
to the development of resources like the
in the Online Supplementary Document.
National Free Diagnostic Service Initiative, which provides services in India [7]. Similar resources for COVID-19 are essential to stopping the
spread of COVID-19 and improving global health.
In addition to the AtM Index, another major effort to improve reporting on AtM programs is Access Accelerated and its Access Observatory, which attempts not only to collect data, which is made publicly available,
but also to devise a standardized measurement framework [8]. Their evaluation of pilot programs in the Philippines and Ghana suggests that differential pricing aided with health care strengthening can increase access
to medicines [9].
A variety of factors continue to serve as barriers to conducting widespread, robust program evaluations, including the lack of specific data about drugs, quality medicine pricing data, and household usage of drugs. In
addition, companies often lack incentives to collect and report high-quality impact data.
Despite these challenges, there are a small number of pharmaceutical companies that have conducted robust evaluations in the past. While none of
The need to promote greater rigor
the 120 AtM initiatives evaluated by Rockers et al. in 2017 met the highand transparency in AtM programs is
quality threshold under the Grading of Recommendations, Assessment,
essential to understanding how well
Development and Evaluation (GRADE) system, three studies were classithese programs are actually doing to
fied as moderate quality: (1) Merck MSD’s Mectizan Donation Program,
(2) the Pfizer International Trachoma Initiative, and (3) Novartis’s Access
achieve desired goals to increase acprogram in Kenya. The Novartis Access study was the first randomized
cess and improve health outcomes.
assessment of the impact of a pharmaceutical industry-led AtM program,
and initial results indicate that even offering medicines at US$1 per treatment per month did not significantly improve overall access nor reduce prices of the medicine after one
year [10]. The study will be extended over a two-year period to test the factors which might have contributed to these results, which underscores the need for rigorous evaluations to understand and overcome
barriers to access.
Program design varies widely between AtM initiatives, with the 120 AtM initiatives assessed in 2017 employing the following strategies: medicine donation (48%), price reduction (44%), licensing agreements (22%),
and supply chain strengthening (11%). It has been found that bulk donations are more likely to be unsustainable and even cause harm in the long run by reducing competition [11]. General price reduction as a strategy
alone may run the risk of not addressing other accessibility issues in a specific region. Increasing the quality of
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The urgent need to overcome COVID-19 has prioritized
AtM among global leaders. In May 2020, the World
Health Assembly adopted a resolution that calls for increased collaboration through “existing mechanisms for
voluntary pooling and licensing of patents” to mitigate
the COVID-19 pandemic and for “equitable access to and
Photo: Image credit: ©pogonici/123RF.COM.
fair distribution of all essential health technologies and
products to combat the novel coronavirus.” The resolution was co-sponsored by more than 130 countries and
adopted by consensus [13]. Coupling expanded access with more rigorous and transparent evaluations will
help ensure that best practices lead to desired outcomes and minimize unintended consequences. Fortunately,
many actors across industry, academia, and public health recognize the need to prioritize equity, accountability, independence, and sound evidence. In doing so, companies can move toward strengthening their reputations while increasing meaningful impact that has the potential to save lives.
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evaluations is necessary to determine the success of certain AtM strategies in a variety of contexts. More innovative, long-term approaches to improving AtM should
also be explored, including differential pricing, voluntary
licensing, and patent pooling [12]. Some of the metrics
revised for the 2021 AtM Index aim to better measure
the scale and long-term sustainability of companies’ AtM
strategies.
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